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Background:  Studies of dipeptidyl peptidase-4 inhibitors (DPP-4i) report heterogeneous effects on endothelial function in patients with 
type 2 diabetes. This study assessed the effects of the DPP-4i linagliptin (LINA) vs the sulfonylurea glimepiride (GLIM) and placebo (PBO) 
on measures of macro- and microvascular function.
methods:  This study (NCT01703286) randomized 42 type 2 diabetes patients with HbA1c ≤7.5%, no micro- or macrovascular disease 
and on stable metformin background to LINA 5 mg qd, GLIM 1-4 mg qd or PBO for 28 days. Fasting and postprandial macrovascular 
endothelial function, measured by brachial flow-mediated vasodilation (FMD), and microvascular function, measured by Laser-Doppler, 
were analyzed after 28 days.
results:  Baseline mean±SD age and BMI were 60.3±6.0 yrs and 30.3±3.0 kg/m2, respectively. After 28 days, changes in fasting FMD 
were similar between the 3 study arms (treatment ratio [gmean±gSE]: LINA vs GLIM, 0.884±1.222; LINA vs PBO, 0.884±1.223; GLIM 
vs PBO, 1.000±1.223; all p=ns). Similarly, no differences were seen in postprandial FMD. LINA significantly improved fasting, but not 
postprandial, microcirculation (figure). LINA had no effect on heart rate or blood pressure. Rates of overall adverse events with LINA, GLIM 
and PBO were 27.5%, 61.0% and 35.0%. Fewer hypoglycemic events were seen with LINA (5.0%) than GLIM (39.0%).
conclusion:  LINA had no effect on macrocirculation in type 2 diabetes, but significantly improved microcirculatory flow in the fasting state.
 
